Lymphoma Clinical Trial
Official title:
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
NCT number | NCT02145559 |
Other study ID # | IRB13-0614 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | April 2014 |
Est. completion date | July 2018 |
Verified date | April 2019 |
Source | University of Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Given the role of mTOR signaling and probable synergistic activity of combining sirolimus and
metformin in patients with advanced solid tumors, the investigators hypothesize that:
1. The combination of metformin plus sirolimus will result in reduction of p4EBP1, p70S6K
and pAKT more than sirolimus alone in peripheral blood T cells (PBTC).
2. The combination of metformin plus sirolimus will result in decreased levels of serum
biomarkers including fasting insulin, C-peptide, glucose, triglycerides, LDH, IGF-1,
IGF-1R, IGF-BP and leptin, but an increase in adiponectin in peripheral blood.
3. Expression of active forms of AMPK, mTOR, PI3K, PTEN loss, AKT, LKB1, P62, LC3, and/or
ULK1 in the tumor tissue (original pathology) will be predictive of response to
combination therapy. This will be an exploratory hypothesis for this study.
4. Sirolimus induced toxicity, especially hyperglycemia and hypertriglyceridemia, will be
mitigated by combining sirolimus with metformin.
5. Metformin plus sirolimus will have promising anti-cancer activity and this activity will
correlate with decreases in the above biomarkers. This will be an exploratory hypothesis
for this study.
Status | Completed |
Enrollment | 24 |
Est. completion date | July 2018 |
Est. primary completion date | November 15, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria 1. Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. 2. ECOG performance status 0 or 1 (See Appendix B). 3. Age = 18 years. 4. Non-pregnant, non-lactating women using adequate contraception. 5. Ability to understand and willingness to sign informed consent. 6. Adequate hematologic, renal and hepatic function, as defined by each of the following: - Absolute neutrophil count (ANC) > l500/µl - Platelets > 100,000/µl - Total bilirubin < 1.5 x upper limit of normal - SGOT and SGPT < 2.5x upper limit of normal for patients without liver metastases or SGOT and - SGPT < 5 x upper limit of normal for patients with liver metastases. - Creatinine < 1.4 mg/dl for females or < 1.5 mg/dl for males. 7. Prior treatment with mTOR inhibitors will be allowed as long as the patient did not have = Grade 3 toxicity attributed to the mTOR inhibitor with prior therapy. 8. Measurable or non-measurable disease will be allowed. 9. Patients taking substrates, inhibitors, or inducers of CYP3A4 (See Appendix C) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with sirolimus. Exclusion Criteria 1. Prior treatment with an mTOR inhibitor (including sirolimus) is allowed; however, patients with = grade 3 toxicities with an mTOR inhibitor are excluded. 2. Fasting glucose > 200 mg/dL or fasting triglycerides > 300 mg/dL. 3. Patients who have had chemotherapy or immunotherapy within 4 weeks of starting study drug, or radiotherapy within 14 days of starting study drug, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. 4. Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exceptions of octreotide LAR (for neuroendocrine tumors) and endocrine therapy (for prostate, breast, or gynecologic malignancies). 5. Serious underlying medical (including acute decompensated congestive heart failure) or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment. Similarly, any unstable medical condition that, in the opinion of the treating physician or study investigators, would interfere with the study objectives. 6. Pregnancy or breastfeeding. 7. Major surgery within 4 weeks. 8. Concurrent use of any proton pump inhibitors, as these limit the absorption of metformin30,41. 9. History of lactic acidosis as per prior medical records or provided by the patient. 10. Metabolic acidosis, acute or chronic. Acidosis will be defined a blood pH < 7.35. Acidosis will be suspected if serum bicarbonate is < 22 mEq/L. In such cases, venous blood pH would be checked to confirm or exclude acidosis. 11. Participants with known uncontrolled diabetes, defined as a hemoglobin A1C of > 8%. 12. Participants who are already on treatment with metformin, except when metformin can be held for 4 weeks prior to the start of the study. 13. History of ongoing alcohol abuse or binge drinking. Alcohol abuse will be defined as a pattern of drinking that results in harm to one's health, interpersonal relationships, and ability to work. Binge drinking will be defined as at least one episode of consuming more than five units in men and four units in women during the previous month. One unit of alcohol can generally said to be a half pint of beer, a single measure (shot glass) of a spirit or a small glass of table wine. |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacodynamic Biomarker p70S6K | To compare the change in the pharmacodynamic biomarker p70S6K in peripheral blood T cells with the combination of metformin XR and sirolimus to that with sirolimus alone. | 28 days | |
Secondary | Pharmacodynamic Biomarkers p4EBP1 and pAKT | To compare the changes in pharmacodynamic biomarkers p4EBP1 and pAKT in peripheral blood T cells with the combination of metformin XR and sirolimus to those with sirolimus alone. | 28 days | |
Secondary | Tolerability - Full physical Exam | To assess the tolerability of the combination of metformin XR plus sirolimus at the selected doses a full history and physical exam will be conducted on days 1, 8, and 15. | 28 day cycles | |
Secondary | Fasting Serum Glucose and Triglycerides | To compare fasting serum glucose and triglycerides on sirolimus before and after the addition of metformin XR. | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |